Expedeon AG, DE000A1RFM03

Expedeon AG, DE000A1RFM03

14.03.2019 - 18:32:53

Expedeon AG: Expedeon Announces Supervisory Board Changes

Ad hoc release according to article 17 MAR 14 March 2019

/

Expedeon Announces Supervisory Board Changes

Heidelberg, Germany and Cambridge, UK, 14 March 2019 - Expedeon AG (Frankfurt: EXN; ISIN: DE000A1RFM03; Prime Standard) today announced that Dr. Cristina Garmendia Mendizábal is to step down as chairwoman of the supervisory board effective April 4, 2019. Dr. Garmendia will shortly be assuming a new role in Spain which she will be unable to combine with her duties at Expedeon AG. Dr. Garmendia will retain her entire shareholding in Expedeon. Joseph Fernandez, deputy chairman of the supervisory board will assume Dr. Garmendia's responsibilities until a suitable successor is found.

*** end of ad hoc announcement ***For further information, please contact:

Expedeon AG Dr. Heikki Lanckriet CEO Phone: +44 1223 873 364 Email: heikki.lanckriet@expedeon.com

MC Services AG (Investor Relations and International Media Relations) Raimund Gabriel Managing Partner Phone: +49 89 210228 0 Email: expedeon@mc-services.eu

About Expedeon AG: www.expedeon.com Expedeon is an enabler of exciting advances in medical science and patient care. The Company's core technologies, innovative products and services are used in research laboratories around the world, enabling scientists to push the boundaries of research and product development, and play an integral part in new diagnostic tools being brought to market. With applications spanning the entire workflows in genomics, proteomics and immunology, Expedeon's technologies both accelerate and simplify research and make new and cost-effective processes available to biopharmaceutical and diagnostic organisations alike, thereby underpinning its customers' development and commercialisation objectives. Expedeon's products are sold through a direct sales force and several distribution partners in Europe, the USA and Asia. Expedeon AG has offices in Germany, Spain, UK, USA and Singapore. The Company is listed on the Prime Standard segment of the Frankfurt Stock Exchange (Ticker: EXN; ISIN: DE000A1RFM03).

This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of Expedeon AG may deviate greatly from the established conclusions or implied predictions contained in such statements. Expedeon does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason.

Contact: David Roth Vorstand/ CFO Expedeon AG Waldhofer Str. 102 69123 Heidelberg, GERMANY Tel. +49 6221 3540 125 Fax. +49 6221 3540 127

14-March-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language: English Company: Expedeon AG Waldhofer Str. 102 69123 Heidelberg

Germany Phone: +49 (0) 6221 3540 125 Fax: +49 (0) 6221 3540 127 E-mail: investors@expedeon.com Internet: www.expedeon.com ISIN: DE000A1RFM03 WKN: A1RFM0 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange   End of Announcement DGAP News Service

787805  14-March-2019 CET/CEST

@ dgap.de